Cambridge Healthtech Institute’s 4th Annual
Bispecific Antibody Therapeutics
January 22-23, 2015
Creating bioactive molecules that are multivalent and multifunctional offers the promise of more effective therapeutics. By binding to at least two molecular targets simultaneously, antibodies are empowered, thereby delivering a highly potent therapeutic, particularly for cancer immunotherapy. This Bispecific Antibody Therapeutics conference explores the challenges of engineering multispecificity to ensure stability and efficacy, and reviews the numerous forms of multispecific antibodies. The conference gives particular focus to safety issues, as well as PK and immunogenicity. Case studies highlight preclinical development as well as clinical data.
Cancer Immunotherapy with Bispecific T Cell Engager (BiTE®) Antibodies
Dirk Nagorsen, M.D., Ph.D., Global Development Leader, Global Clinical Development, Amgen Research Munich GmbH
A Novel Fc-Containing Bispecific Format with Full-Length Antibody Properties: Applications in Oncology
David Szymkowski, Ph.D., Senior Director, Biotherapeutics, Xencor, Inc.
Enhanced Tumor Cell Killing via Selective Inhibition of CD47 with Bispecific Antibodies
Nicolas Fischer, Ph.D., Head, Research, Novimmune SA
A New Platform to Automate Bispecific Antibody Design and Assessment
Christopher Smith, Ph.D., Senior Scientific Consultant, Biologics, Genedata
MM-141, an IGF-IR- and ErbB3-Directed Bispecific Antibody, Overcomes Adaptations in
Growth Factor Signaling Networks
Alexey A. Lugovskoy, Ph.D., Vice President, Therapeutics and MM-141 Project Leader, Merrimack Pharmaceuticals, Inc.
Therapeutic Fully Human Bispecific Antibodies with Two Binding Sites in Each Fv Region
Kristian Jensen, Ph.D., Vice President, Project Management, R&D, Dutalys GmbH
A Novel and Generic Approach for the Generation of Monovalent Bispecific IgG
Yariv Mazor, Ph.D., Scientist, Antibody Discovery and Protein Engineering, Medimmune
Nonclinical Development of Multi-Targeting Biotherapeutics: More Targets, More Complexity
Rodney Prell, Ph.D., Senior Scientist, Toxocology, Genentech, Inc.
Engineering Bispecific Antibody through Electrostatic Steering Mechanism:
Heavy Chain Heterodimerization and Light – Heavy Chain Pairing
Gunasekaran Kannan, Ph.D., Principal Scientist and Group Leader, Biologics Optimization, Amgen, Inc.
Computer-Based Design of Bispecific Antibodies
Brian Kuhlman, Ph.D., Professor, Biochemistry and Biophysics, University of North Carolina School of Medicine
Novel Approach to Hemophilia A Treatment: ACE910, an Asymmmetric Bispecific IgG
to Coagulation Factors IXa and X
Yukiko Okuyama-Nishida, Ph.D., Sub Lifecycle Leader, Primary Lifecycle Management, Chugai Pharmaceutical Co., Ltd.
DuoBody® Platform: A Versatile Platform for Lead Discovery in the Final Format
Aran F. Labrijn, Ph.D., Senior Scientist, Antibody Sciences, Genmab BV
Preclinical Development of a Fully Human Bispecific Antibody Platform
Eric Smith, Ph.D., Associate Director, Bispecifics, Regeneron Pharmaceuticals, Inc.